Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 49 entries
View as:

MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity

Phase: N/A Priority: Normal
NCT ID: NCT01313767 Org: User:
Start: 03/31/11 End: 02/29/12 Due: 02/28/13

Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Phase: N/A Priority: Normal
NCT ID: NCT05195112 Org: User:
Start: 12/24/21 End: 02/18/23 Due: 02/18/24

Pivotal Clinical Study to Assess the Anti-adhesive Effect and Safety of ABT13107 Applied to Postoperative Intrauterine

Phase: N/A Priority: Normal
NCT ID: NCT04007211 Org: User:
Start: 02/27/17 End: 08/29/18 Due: 08/29/19

Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold

Phase: N/A Priority: Normal
NCT ID: NCT02751034 Org: User:
Start: 06/30/13 End: 01/31/14 Due: 01/31/15

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT03216408 Org: User:
Start: 03/30/16 End: 03/07/17 Due: 03/07/18

Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

Phase: N/A Priority: Normal
NCT ID: NCT01259557 Org: User:
Start: 08/31/10 End: 08/31/11 Due: 08/31/12

The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy

Phase: N/A Priority: Normal
NCT ID: NCT01256021 Org: User:
Start: 08/31/10 End: 05/31/11 Due: 05/31/12

Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT03289169 Org: User:
Start: 12/30/16 End: 05/29/19 Due: 05/29/20

Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia

Phase: N/A Priority: Normal
NCT ID: NCT01588574 Org: User:
Start: 08/31/12 End: 12/31/13 Due: 12/31/14

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT03837561 Org: User:
Start: 12/13/18 End: 06/03/19 Due: 06/03/20

Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®

Phase: N/A Priority: Normal
NCT ID: NCT04281745 Org: User:
Start: 10/17/19 End: 03/16/22 Due: 03/16/23

Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03905291 Org: User:
Start: 07/31/18 End: 12/26/18 Due: 12/26/19

MEDITOXIN® in Treatment of Crow's Feet Line

Phase: N/A Priority: Normal
NCT ID: NCT03317574 Org: User:
Start: 08/17/17 End: 05/14/18 Due: 05/14/19

Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®

Phase: N/A Priority: Normal
NCT ID: NCT03796351 Org: User:
Start: 09/30/12 End: 01/31/13 Due: 01/31/14

Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT03371342 Org: User:
Start: 12/13/17 End: 09/05/18 Due: 09/05/19

Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT01237977 Org: User:
Start: 11/23/09 End: 09/30/10 Due: 09/30/11

Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers

Phase: N/A Priority: Normal
NCT ID: NCT03647982 Org: User:
Start: 03/20/18 End: 11/20/18 Due: 11/20/19

Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity

Phase: N/A Priority: Normal
NCT ID: NCT02757404 Org: User:
Start: 05/30/16 End: 08/16/16 Due: 08/16/17

MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity

Phase: N/A Priority: Normal
NCT ID: NCT03908580 Org: User:
Start: 09/06/13 End: 03/31/15 Due: 03/31/16

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Phase: N/A Priority: Normal
NCT ID: NCT04144049 Org: User:
Start: 09/10/19 End: 04/23/20 Due: 04/23/21

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

Phase: N/A Priority: Normal
NCT ID: NCT03216473 Org: User:
Start: 05/25/16 End: 07/04/17 Due: 07/04/18

MT10109L in the Treatment of Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT03795922 Org: User:
Start: 12/24/18 End: 01/25/21 Due: 01/25/22

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT01485601 Org: User:
Start: 12/07/11 End: 08/17/12 Due: 08/17/13

Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03547141 Org: User:
Start: 04/16/18 End: 11/01/18 Due: 11/01/19

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT04143815 Org: User:
Start: 05/20/19 End: 09/01/20 Due: 09/01/21